165 related articles for article (PubMed ID: 34634898)
1. Pulmonary adverse events due to immune checkpoint inhibitors: A literature review.
Georgakopoulou VE; Garmpis N; Mermigkis D; Damaskos C; Chlapoutakis S; Mantzouranis K; Gkoufa A; Papageorgiou C; Garmpi A; Makrodimitri S; Diamantis E; Sklapani P; Trakas N; Tsiafaki X
Monaldi Arch Chest Dis; 2021 Oct; 92(2):. PubMed ID: 34634898
[TBL] [Abstract][Full Text] [Related]
2. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist.
Jamal S; Hudson M; Fifi-Mah A; Ye C
J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203
[TBL] [Abstract][Full Text] [Related]
3. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Reese SW; Cone E; Marchese M; Garcia B; Chou W; Ayub A; Kilbridge K; Weinhouse G; Trinh QD
Lung; 2021 Apr; 199(2):199-211. PubMed ID: 33616727
[TBL] [Abstract][Full Text] [Related]
4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
5. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.
Shannon VR; Anderson R; Blidner A; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson DB; Suarez-Almazor ME; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6145-6157. PubMed ID: 32880733
[TBL] [Abstract][Full Text] [Related]
6. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features.
Porcu M; De Silva P; Solinas C; Battaglia A; Schena M; Scartozzi M; Bron D; Suri JS; Willard-Gallo K; Sangiolo D; Saba L
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30841554
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
[TBL] [Abstract][Full Text] [Related]
9. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary Toxicities of Immunotherapy.
Altan M; Zhong L; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2021; 1342():357-375. PubMed ID: 34972974
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
Park H; Hatabu H; Ricciuti B; Aijazi SJ; Awad MM; Nishino M
Eur J Radiol; 2020 Nov; 132():109275. PubMed ID: 32949913
[TBL] [Abstract][Full Text] [Related]
13. Sarcoid-like Reaction Discovered on EBUS-TBNA of Intrathoracic Lymph Nodes During Immunotherapy for Metastatic Melanoma.
Frohlich M; Wang H; Sakr L
J Immunother; 2020; 43(2):75-78. PubMed ID: 31567703
[TBL] [Abstract][Full Text] [Related]
14. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor].
Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Li Y; Liu X; Wang M; Shi J; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):621-626. PubMed ID: 31650943
[TBL] [Abstract][Full Text] [Related]
16. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
[TBL] [Abstract][Full Text] [Related]
17. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
Klein BA; Alves FA; de Santana Rodrigues Velho J; Vacharotayangul P; Hanna GJ; LeBoeuf NR; Shazib MA; Villa A; Woo SB; Sroussi H; Sonis S; Treister NS
Oral Dis; 2022 Jan; 28(1):9-22. PubMed ID: 34265157
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy.
Possick JD
Clin Chest Med; 2017 Jun; 38(2):223-232. PubMed ID: 28477635
[TBL] [Abstract][Full Text] [Related]
19. Rheumatological adverse events secondary to immune checkpoint inhibitors.
Garbarino MC; Manzano N; Messina O; Zylberman M
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):215-222. PubMed ID: 37005129
[TBL] [Abstract][Full Text] [Related]
20. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.
Inthasot V; Bruyneel M; Muylle I; Ninane V
Acta Clin Belg; 2020 Aug; 75(4):308-310. PubMed ID: 31179880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]